Relay Therapeutics announces Pfizer collaboration and three new pipeline programs

Relay Therapeutics, Inc.

Clinical collaboration with Pfizer to evaluate RLY-2608 + atirmociclib + fulvestrant in PI3Kα-mutated HR+/HER2- metastatic breast cancer; initiation planned by end of 2024.
New pre-clinical programs: vascular malformations, Fabry disease non-inhibitory chaperone, and NRAS-selective inhibitor, targeting over 200,000 U.S. patients.
RLY-2608 clinical development in vascular malformations expected Q1 2025; Fabry disease chaperone and NRAS inhibitor to enter clinic in H2 2025.
Cash runway guidance unchanged; $750 million expected to fund operations into second half of 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.